New formulation of non-Hodgkin Lymphoma drug approved


European regulators have approved a subcutaneous form of MabThera for non-Hodgkin Lymphoma. This reduces patient treatment time from 2.5 hours to 5 minutes.

Up to now, the approved way of administering the drug was intravenous.

The green light for Roche's new MabThera formulation follows on from the European approval for a subcutaneous form of the breast cancer drug Herceptin last September.

Last November, U.S. health regulators approved its drug Gazyva as a treatment for chronic lymphocytic leukemia (CLL). Roche is also testing the drug in patients with non-Hodgkin's Lymphoma.

The drugmaker has also won approval for two new breast cancer drugs, Perjeta and Kadcyla.


Source: Reuters:

Login to your account

Did you forget your password?